Liandong Ma

662 total citations
26 papers, 486 citations indexed

About

Liandong Ma is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Liandong Ma has authored 26 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Liandong Ma's work include Drug Transport and Resistance Mechanisms (6 papers), Protein Degradation and Inhibitors (5 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Liandong Ma is often cited by papers focused on Drug Transport and Resistance Mechanisms (6 papers), Protein Degradation and Inhibitors (5 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Liandong Ma collaborates with scholars based in United States, Switzerland and China. Liandong Ma's co-authors include Christopher A. Slapak, Sandaruwan Geeganage, Michael Flagella, Jennifer D. Davidson, Lawrence M. Gelbert, Krishnamachary Nandigama, Melvin S. Center, Anne H. Dantzig, Susan E. Pratt and Alfred Penfornis and has published in prestigious journals such as Blood, Biochemistry and Cancer Research.

In The Last Decade

Liandong Ma

24 papers receiving 470 citations

Peers

Countries citing papers authored by Liandong Ma

Since Specialization

Citations

This map shows the geographic impact of Liandong Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liandong Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liandong Ma more than expected).

Fields of papers citing papers by Liandong Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liandong Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liandong Ma. The network helps show where Liandong Ma may publish in the future.

Co-authorship network of co-authors of Liandong Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Liandong Ma. A scholar is included among the top collaborators of Liandong Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liandong Ma. Liandong Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia 2025 ·Blood ·(unknown), (unknown), (unknown), Hideaki Mizuno, Po Yee Mak, (unknown), Steffen Boettcher, Liandong Ma, (unknown), Branko Cuglievan, Alexandra M. Stevens, Michael Andreeff, Yuki Nishida	0
2	Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells 2024 ·Blood ·(unknown), Hideaki Mizuno, Edward Ayoub, Eiji Sugihara, (unknown), (unknown), (unknown), Po Yee Mak, Baozhen Ke, Bing Z. Carter, Abhishek Maiti, Liandong Ma, Michael Andreeff	1
3	Abstract 3297: Discovery and evaluation of GT19870, a GSPT1/Myc molecular glue drug (MGD) with oral bioavailability for targeting c-Myc and n-Myc-addictive blood cancer and solid tumors 2024 ·Cancer Research ·Liandong Ma, Youzhi Tong, (unknown), (unknown), (unknown), Ru Xu, (unknown)	1
4	A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations 2023 ·Acta Crystallographica Section F Structural Biology Communications ·S.K. Doamekpor, (unknown), Ruo Xu, Liandong Ma, Youzhi Tong, Liang Tong	3
5	C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill in vitro and in vivo in Acute Myeloid Leukemia and Lymphomas 2022 ·(unknown), (unknown), Edward Ayoub, (unknown), (unknown), Vivian Ruvolo, Po Yee Mak, Bing Z. Carter, (unknown), Abhishek Maiti, (unknown), (unknown), (unknown), Liandong Ma, Michael Andreeff	1
6	C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas 2022 ·Blood ·Yuki Nishida, (unknown), Edward Ayoub, (unknown), Vivian Ruvolo, Po Yee Mak, Bing Z. Carter, Steffen Boettcher, Abhishek Maiti, (unknown), (unknown), (unknown), Liandong Ma, Michael Andreeff	6
7	Abstract 5274: Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients 2022 ·Cancer Research ·Liandong Ma, Youzhi Tong, (unknown), (unknown), Xiaodan Hou, (unknown), Jiangwei Li, Huiyuan Wang, Weidong Qian, Yu Zhang, Andy Goren, Arul M. Chinnaiyan	0
8	Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer 2021 ·Breast Cancer Research and Treatment ·Huiping Li, Guohong Song, (unknown), Ran Ran, Hanfang Jiang, Ruyan Zhang, Yaxin Liu, (unknown), (unknown), Liandong Ma, Ye Sun, Meiyu Wang, Qingqing Zhou, (unknown), (unknown), (unknown), Youzhi Tong	5
9	Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models 2017 ·Cancer Research ·Suzane L. Um, Victoria L. Peek, Jennifer R. Stephens, (unknown), (unknown), Joel D. Cook, Isabella H. Wulur, (unknown), Sudhakar Chintharlapalli, Robert J. Evans, William J. Feaver, Lysiane Huber, Linda N. Lee, Ling Liu, Liandong Ma, Ruslan D. Novosiadly, Volker Wacheck, S. Betty Yan	2
10	Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model 2011 ·Investigational New Drugs ·Timothy P. Burkholder, (unknown), (unknown), James R. Henry, (unknown), David Mendel, (unknown), (unknown), David A. Barda, Eileen L. Considine, Mark Uhlik, Yuefeng Chen, Liandong Ma, Laura J. Bloem, Jacqueline K. Akunda, Denis McCann, Manuel Sánchez-Félix, David K. Clawson, Michael Lahn, James J. Starling	16
11	Abstract 2820: LY2784544, a small molecule JAK2 inhibitor, induces apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway 2011 ·Cancer Research ·Liandong Ma, Baohui Zhao, Richard A. Walgren, (unknown), Timothy P. Burkholder	2
12	LY2784544, a Novel JAK2 Inhibitor, Decreases In Vitro Growth of Hematopoietic Human Progenitors From JAK2 V617F Positive Polycythemia Vera Patients 2010 ·Blood ·Lourdes Florensa, Beatríz Bellosillo, Leonor Arenillas, Liandong Ma, Richard A. Walgren, Alberto Álvarez, (unknown), (unknown), Raquel Longarón, Carles Besses	3
13	An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines 2004 ·Cancer Research ·Jennifer D. Davidson, Liandong Ma, Michael Flagella, Sandaruwan Geeganage, Lawrence M. Gelbert, Christopher A. Slapak	249
14	Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP-binding cassette (ABC) drug transporters 2003 ·Biochemical Pharmacology ·Anne H. Dantzig, Robert L. Shepard, Susan E. Pratt, Linda B. Tabas, Peter A. Lander, Liandong Ma, Donald C. Paul, Daniel C. Williams, Sheng-Bin Peng, Christopher A. Slapak, N Godinot, William L. Perry	31
15	Identification and characterization of the canine multidrug resistance-associated protein. 2002 ·PubMed ·Liandong Ma, Susan E. Pratt, Jin Cao, Anne H. Dantzig, Robert E. Moore, Christopher A. Slapak	20
16	Parathyroid hormone (hPTH 1–38) stimulates the expression of UBP41, an ubiquitin‐specific protease, in bone 2002 ·Journal of Cellular Biochemistry ·Rebecca R. Miles, James P. Sluka, David L. Halladay, Robert F. Santerre, Laura V. Hale, Laura J. Bloem, (unknown), Rachelle J. Sells Galvin, Liandong Ma, Janet M. Hock, J.E. Onyia	17
17	Evaluation of TAP1 polymorphisms with insulin dependent diabetes mellitus in finnish diabetic patients 1997 ·Human Immunology ·Liandong Ma, Alfred Penfornis, (unknown), David Schoenfeld, Eva Tuomilehto‐Wolf, (unknown), G. A. Hitman, Denise L. Faustman	16
18	Human TAP1 polymorphisms detected by denaturing gradient gel electrophoresis 1997 ·Tissue Antigens ·Lijia Shi, Gang Yan, Yang Fu, Liandong Ma, Alfred Penfornis, Denise L. Faustman	10
19	Screening of the TAP1 gene by denaturing gradient gel electrophoresis in insulin‐dependent diabetes mellitus: detection and comparison of new polymorphisms between patients and controls 1997 ·Tissue Antigens ·Gang Yan, Lijia Shi, Yang Fu, Xiaoying Wang, David Schoenfeld, Liandong Ma, Alfred Penfornis, Howard M. Gebel, Denise L. Faustman	10
20	Phosphorylation of the Multidrug Resistance Encoded Protein P190 1995 ·Biochemistry ·Liandong Ma, Krishnamachary Nandigama, Melvin S. Center	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact